RxDoctor Payments Data

Kristin Smith

Family · Ellaville, GANPI 1720573637

Payments from drug & device makers

$1,099in general payments, 2019–2025

Across 58 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$212
  • GSK$185
  • Sumitomo Pharma America, Inc.$178
  • Corcept Therapeutics$110
  • Lilly USA, LLC$62
  • Novartis$59
  • plus $293 from 11 others

What the payments were for

  • Food & beverage$1,099100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,099 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$34,599
Medicare patients
237
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$129,754
EliquisApixaban73$72,064
JardianceEmpagliflozin47$59,003
MounjaroTirzepatide51$54,009
BiktarvyBictegrav/Emtricit/Tenofov Ala13$48,650
XareltoRivaroxaban49$39,837
FarxigaDapagliflozin Propanediol38$37,269
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$33,280
TrulicityDulaglutide15$29,158
GemtesaVibegron47$27,078
MyrbetriqMirabegron28$19,566
JanuviaSitagliptin Phosphate15$18,813
Bydureon BciseExenatide Microspheres15$12,209
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$11,751
SymbicortBudesonide/Formoterol Fumarate31$7,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp$212$134,161130 claims
Lilly USA, LLCMounjaro, Trulicity$62$83,16766 claims
AstraZenecaFarxiga, Symbicort$34$45,10469 claims
Johnson & JohnsonXarelto$18$39,83749 claims
GSKTrelegy Ellipta$185$33,28042 claims
Sumitomo Pharma America, Inc.Gemtesa$178$27,07847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.

Other family in Ellaville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →